
Join to view full profile
4710 North HabanaTampa, FL 33614
Phone+1 813-450-3457
Fax+1 877-235-3648
Dr. Welton is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Laurie Welton is an Infectious Disease specialist She graduated from Michigan State University College of Osteopathic Medicine in 1992, and completed her fellowship in Infectious Disease at Beaumont Health (Royal Oak) from 1995 to 1997. Having contributions in academic publications, her work on antimicrobial resistance is published in Antimicrob Agents Chemother. Dr. Welton is engaged in various clinical trials, including studies in treatment-refractory MAC Lung Disease and Outpatients with COVID-19. She earned the CMS Meaningful Use Stage 1 Certification from SuiteMed EMR, Fox Meadows Software in 2011-2013.
Education & Training
Corewell Health William Beaumont University HospitalFellowship, Infectious Disease, 1995 - 1997
Michigan State University College of Osteopathic MedicineClass of 1992
Certifications & Licensure
FL State License 2003 - 2028
GA State License 2026 - 2028
OR State License 2018 - 2027
MT State License 2024 - 2026
WA State License 2016 - 2026
MI State License 1995 - 2004
AOA Board of Internal Medicine Infectious Disease
AOA Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification IMS, MedPharm Services LLC, 2012-2017
- CMS Meaningful Use Stage 1 Certification Intelligent Medical Software (IMS), SuiteMed, 2012-2017
- CMS Meaningful Use Stage 1 Certification SuiteMed EMR, Fox Meadows Software, 2011-2013
Clinical Trials
- ACTIV-2: A Study for Outpatients With COVID-19 Start of enrollment: 2020 Aug 19
- RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease Start of enrollment: 2020 Dec 01
- Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease Start of enrollment: 2022 May 20
Publications & Presentations
PubMed
- 75 citationsAntimicrobial Resistance in Enterococci Isolated from Turkey Flocks Fed VirginiamycinL. A. Welton, L. A. Thal, Mary Beth Perri, Susan M. Donabedian, J. McMahon
Antimicrobial Agents and Chemotherapy. 1998-03-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: